Using bacteria's natural predator, the bacteriophage, we are able to overcome incurable and deadly infectious diseases.
Phagos has raised €27M across 2 funding rounds from 13 investors, most recently a Series A round in Oct 2025. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-10-09 | Series A | €25M | Acurio Ventures,Capagro,CapHorn Invest,Citizen Capital,Demeter,Entrepreneurs First+3 more | View deal → |
| 2022-09-28 | Other | €2.4M | AgFunder,Entrepreneur First,Grant Aarons,Max Jamily | View deal → |
